Core Viewpoint - Aibo Medical has a strong market share and leading position in the ophthalmic surgery and myopia prevention market in China, with a rapidly growing vision care business and plans to expand into high-comfort, functional consumer products [1] Group 1 - The company has a high market share in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently in a rapid growth phase [1] - The company is accelerating its expansion into high-comfort and functional consumer product markets [1]

Core Viewpoint - The company leverages five proprietary technology platforms to develop innovative products that are both domestically pioneering and internationally leading [1] Group 1: Company Strategy - The company adheres to a dual-driven strategy of "medical + consumer" and internationalization, aiming for steady and sustainable high-quality development [1]

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...

Group 1 - The company, Aibo Medical (688050.SH), holds a significant market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company expresses strong confidence in its future development and will continue to actively promote market expansion [1]

Group 1 - The company has a high market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company is confident about its future development and will continue to actively promote market expansion [1]

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...

来源：扬州国金集团 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ 热文： 投资人"忙疯了" 2026年1月23日，爱博弘盛（扬州）股权投资基金合伙企业（有限合伙）完成工商登记，标志着 扬州市首支CVC生物医药产业子基金顺利落地。该基金由国信弘盛私募基金管理有限公司担任基 金管理人及执行事务合伙人，联合爱博医疗（688050.SH）、扬州市生物医药产业投资基金、广 陵区共同出资设立， 总认缴规模5亿元。 据悉，该基金未来将联合产业龙头与地方国资，以"产业+资本+券商资源"为核心模式，聚焦生物 医药赛道，开展专业化投资布局。 ...

Core Viewpoint - Aibono Medical and Hong Kong Polytechnic University have signed a cooperation agreement to enhance collaboration in research and clinical transformation, as well as talent cultivation in the field of ophthalmology [1][2]. Group 1: Collaboration Details - The partnership aims to establish a long-term strategic collaboration mechanism focusing on three core dimensions: joint research and development, clinical transformation, and talent cultivation [1]. - Aibono Medical emphasizes innovation as a driving force for development and seeks to integrate industry resources with academic research advantages through this collaboration [1]. - The collaboration will focus on myopia prevention and optical technology, with both parties leveraging their strengths to overcome key technological bottlenecks in the industry [1][2]. Group 2: Talent Development and Application - Aibono Medical will provide scholarships and research practice opportunities, while the university will contribute its talent cultivation and global resources to create a joint training mechanism [2]. - The partnership will also explore cutting-edge technologies for myopia control in collaboration with the university's startup, Tongyan Technology Co., Ltd., facilitating the commercialization of academic research outcomes [2].

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

Core Viewpoint - Aibao Medical has signed a cooperation agreement with Hong Kong Polytechnic University to enhance collaboration in research and development, clinical translation, and talent cultivation in the field of ophthalmology [1][2] Group 1: Collaboration Details - The partnership aims to establish a long-term strategic collaboration mechanism, focusing on integrating industry resources and academic research advantages to improve the efficiency of research results and their implementation [1] - Both parties will work closely on myopia prevention and optical technology, leveraging their respective strengths to overcome key technological bottlenecks in the industry [1][2] Group 2: Talent Development and Innovation - Aibao Medical will provide research practice and internship opportunities through its ophthalmology scholarship, while the university will utilize its advantages in talent cultivation and global resources to create a joint training mechanism [2] - The collaboration will also explore cutting-edge technologies for myopia control in partnership with the university's startup, Tongyan Technology Co., Ltd., facilitating the industrialization of academic research outcomes [2] Group 3: Broader Impact - The agreement is seen as a new starting point for Aibao Medical, aiming to elevate Chinese ophthalmic technology to the international stage [2] - The collaboration is expected to serve as a model for Beijing-Hong Kong technology cooperation, enhancing technological exchanges and promoting industrial synergy between the two regions [2]